<billStatus>
 <version>
  3.0.0
 </version>
 <bill>
  <number>
   1873
  </number>
  <updateDate>
   2023-01-11T13:48:16Z
  </updateDate>
  <updateDateIncludingText>
   2023-01-11T13:48:16Z
  </updateDateIncludingText>
  <originChamber>
   House
  </originChamber>
  <type>
   HR
  </type>
  <introducedDate>
   2021-03-12
  </introducedDate>
  <congress>
   117
  </congress>
  <constitutionalAuthorityStatementText>
   &lt;pre&gt;[Congressional Record Volume 167, Number 47 (Friday, March 12, 2021)][House]From the Congressional Record Online through the Government Publishing Office [&lt;a href="https://www.gpo.gov"&gt;www.gpo.gov&lt;/a&gt;]By Mr. BUCSHON:H.R. 1873.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clause 3[Page H1364]&lt;/pre&gt;
  </constitutionalAuthorityStatementText>
  <committees>
   <item>
    <systemCode>
     hsif00
    </systemCode>
    <name>
     Energy and Commerce Committee
    </name>
    <chamber>
     House
    </chamber>
    <type>
     Standing
    </type>
    <subcommittees>
     <item>
      <systemCode>
       hsif14
      </systemCode>
      <name>
       Health Subcommittee
      </name>
      <activities>
       <item>
        <name>
         Referred to
        </name>
        <date>
         2021-03-16T14:32:40Z
        </date>
       </item>
      </activities>
     </item>
    </subcommittees>
    <activities>
     <item>
      <name>
       Referred to
      </name>
      <date>
       2021-03-12T15:33:05Z
      </date>
     </item>
    </activities>
   </item>
  </committees>
  <relatedBills>
   <item>
    <title>
     Lower Costs, More Cures Act of 2021
    </title>
    <congress>
     117
    </congress>
    <number>
     19
    </number>
    <type>
     HR
    </type>
    <latestAction>
     <actionDate>
      2021-10-19
     </actionDate>
     <text>
      Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
     </text>
    </latestAction>
    <relationshipDetails>
     <item>
      <type>
       Related bill
      </type>
      <identifiedBy>
       CRS
      </identifiedBy>
     </item>
    </relationshipDetails>
   </item>
   <item>
    <title>
     Advancing Education on Biosimilars Act of 2021
    </title>
    <congress>
     117
    </congress>
    <number>
     164
    </number>
    <type>
     S
    </type>
    <latestAction>
     <actionDate>
      2021-04-23
     </actionDate>
     <text>
      Became Public Law No: 117-8.
     </text>
    </latestAction>
    <relationshipDetails>
     <item>
      <type>
       Identical bill
      </type>
      <identifiedBy>
       CRS
      </identifiedBy>
     </item>
    </relationshipDetails>
   </item>
  </relatedBills>
  <actions>
   <item>
    <actionDate>
     2021-03-16
    </actionDate>
    <committees>
     <item>
      <systemCode>
       hsif14
      </systemCode>
      <name>
       Health Subcommittee
      </name>
     </item>
    </committees>
    <sourceSystem>
     <code>
      1
     </code>
     <name>
      House committee actions
     </name>
    </sourceSystem>
    <text>
     Referred to the Subcommittee on Health.
    </text>
    <type>
     Committee
    </type>
   </item>
   <item>
    <actionDate>
     2021-03-12
    </actionDate>
    <text>
     Referred to the House Committee on Energy and Commerce.
    </text>
    <type>
     IntroReferral
    </type>
    <actionCode>
     H11100
    </actionCode>
    <sourceSystem>
     <code>
      2
     </code>
     <name>
      House floor actions
     </name>
    </sourceSystem>
    <committees>
     <item>
      <systemCode>
       hsif00
      </systemCode>
      <name>
       Energy and Commerce Committee
      </name>
     </item>
    </committees>
   </item>
   <item>
    <actionDate>
     2021-03-12
    </actionDate>
    <text>
     Introduced in House
    </text>
    <type>
     IntroReferral
    </type>
    <actionCode>
     Intro-H
    </actionCode>
    <sourceSystem>
     <code>
      9
     </code>
     <name>
      Library of Congress
     </name>
    </sourceSystem>
   </item>
   <item>
    <actionDate>
     2021-03-12
    </actionDate>
    <text>
     Introduced in House
    </text>
    <type>
     IntroReferral
    </type>
    <actionCode>
     1000
    </actionCode>
    <sourceSystem>
     <code>
      9
     </code>
     <name>
      Library of Congress
     </name>
    </sourceSystem>
   </item>
  </actions>
  <sponsors>
   <item>
    <bioguideId>
     B001275
    </bioguideId>
    <fullName>
     Rep. Bucshon, Larry [R-IN-8]
    </fullName>
    <firstName>
     Larry
    </firstName>
    <lastName>
     Bucshon
    </lastName>
    <party>
     R
    </party>
    <state>
     IN
    </state>
    <district>
     8
    </district>
    <isByRequest>
     N
    </isByRequest>
   </item>
  </sponsors>
  <cosponsors>
   <item>
    <bioguideId>
     P000608
    </bioguideId>
    <fullName>
     Rep. Peters, Scott H. [D-CA-52]
    </fullName>
    <firstName>
     Scott
    </firstName>
    <lastName>
     Peters
    </lastName>
    <party>
     D
    </party>
    <state>
     CA
    </state>
    <middleName>
     H.
    </middleName>
    <district>
     52
    </district>
    <sponsorshipDate>
     2021-03-12
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
  </cosponsors>
  <policyArea>
   <name>
    Health
   </name>
  </policyArea>
  <subjects>
   <legislativeSubjects>
    <item>
     <name>
      Drug safety, medical device, and laboratory regulation
     </name>
    </item>
    <item>
     <name>
      Government information and archives
     </name>
    </item>
    <item>
     <name>
      Health personnel
     </name>
    </item>
    <item>
     <name>
      Licensing and registrations
     </name>
    </item>
    <item>
     <name>
      Medical education
     </name>
    </item>
    <item>
     <name>
      Prescription drugs
     </name>
    </item>
   </legislativeSubjects>
   <policyArea>
    <name>
     Health
    </name>
   </policyArea>
  </subjects>
  <summaries>
   <summary>
    <versionCode>
     00
    </versionCode>
    <actionDate>
     2021-03-12
    </actionDate>
    <actionDesc>
     Introduced in House
    </actionDesc>
    <updateDate>
     2021-05-24T13:43:19Z
    </updateDate>
    <text>
     &lt;p&gt;&lt;b&gt;Advancing Education on Biosimilars Act of 2021&lt;/b&gt;&lt;/p&gt; &lt;p&gt;This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)&lt;br&gt; &lt;br&gt; The FDA may also maintain and operate a website to provide educational materials about biological products.&lt;/p&gt;
    </text>
   </summary>
  </summaries>
  <title>
   Advancing Education on Biosimilars Act of 2021
  </title>
  <titles>
   <item>
    <titleType>
     Display Title
    </titleType>
    <title>
     Advancing Education on Biosimilars Act of 2021
    </title>
   </item>
   <item>
    <titleType>
     Official Title as Introduced
    </titleType>
    <title>
     To educate health care providers and the public on biosimilar biological products, and for other purposes.
    </title>
    <billTextVersionName>
     Introduced in House
    </billTextVersionName>
    <billTextVersionCode>
     IH
    </billTextVersionCode>
   </item>
   <item>
    <titleType>
     Short Title(s) as Introduced
    </titleType>
    <title>
     Advancing Education on Biosimilars Act of 2021
    </title>
    <billTextVersionName>
     Introduced in House
    </billTextVersionName>
    <billTextVersionCode>
     IH
    </billTextVersionCode>
   </item>
  </titles>
  <textVersions>
   <item>
    <type>
     Introduced in House
    </type>
    <date>
     2021-03-12T05:00:00Z
    </date>
    <formats>
     <item>
      <url>
       https://www.govinfo.gov/content/pkg/BILLS-117hr1873ih/xml/BILLS-117hr1873ih.xml
      </url>
     </item>
    </formats>
   </item>
  </textVersions>
  <latestAction>
   <actionDate>
    2021-03-16
   </actionDate>
   <text>
    Referred to the Subcommittee on Health.
   </text>
  </latestAction>
 </bill>
 <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
  <dc:format>
   text/xml
  </dc:format>
  <dc:language>
   EN
  </dc:language>
  <dc:rights>
   Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
  </dc:rights>
  <dc:contributor>
   Congressional Research Service, Library of Congress
  </dc:contributor>
  <dc:description>
   This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.
  </dc:description>
 </dublinCore>
</billStatus>

2021-03-16
Health Subcommittee
hsif14
1
House committee actions
Referred to the Subcommittee on Health.
Committee
H11100
2021-03-12
Energy and Commerce Committee
hsif00
2
House floor actions
Referred to the House Committee on Energy and Commerce.
IntroReferral
Intro-H
2021-03-12
9
Library of Congress
Introduced in House
IntroReferral
1000
2021-03-12
9
Library of Congress
Introduced in House
IntroReferral
2021-03-12T15:33:05Z
Referred to
House
Energy and Commerce Committee
2021-03-16T14:32:40Z
Referred to
Health Subcommittee
hsif14
hsif00
Standing
P000608
52
Scott
Rep. Peters, Scott H. [D-CA-52]
Peters
H.
D
2021-03-12
CA
Congressional Research Service, Library of Congress
This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
2021-03-12
2021-03-16
Referred to the Subcommittee on Health.
House
Health
2021-10-19
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
CRS
Related bill
Lower Costs, More Cures Act of 2021
HR
2021-04-23
Became Public Law No: 117-8.
CRS
Identical bill
Advancing Education on Biosimilars Act of 2021
S
B001275
8
Larry
Rep. Bucshon, Larry [R-IN-8]
N
Bucshon
R
IN
Drug safety, medical device, and laboratory regulation Government information and archives Health personnel Licensing and registrations Medical education Prescription drugs
2021-03-12
Introduced in House
 <p><b>Advancing Education on Biosimilars Act of 2021</b></p> <p>This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)<br> <br> The FDA may also maintain and operate a website to provide educational materials about biological products.</p>
2021-05-24T13:43:19Z
00
2021-03-12T05:00:00Z
Introduced in House
https://www.govinfo.gov/content/pkg/BILLS-117hr1873ih/xml/BILLS-117hr1873ih.xml
Advancing Education on Biosimilars Act of 2021
Advancing Education on Biosimilars Act of 2021
Display Title
IH
Introduced in House
To educate health care providers and the public on biosimilar biological products, and for other purposes.
Official Title as Introduced
IH
Introduced in House
Advancing Education on Biosimilars Act of 2021
Short Title(s) as Introduced
HR
2023-01-11T13:48:16Z
2023-01-11T13:48:16Z
3.0.0
2021-10-19
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
CRS
Related bill
Lower Costs, More Cures Act of 2021
HR
2021-04-23
Became Public Law No: 117-8.
CRS
Identical bill
Advancing Education on Biosimilars Act of 2021
S
2021-03-16
Health Subcommittee
hsif14
1
House committee actions
Referred to the Subcommittee on Health.
Committee
H11100
2021-03-12
Energy and Commerce Committee
hsif00
2
House floor actions
Referred to the House Committee on Energy and Commerce.
IntroReferral
Intro-H
2021-03-12
9
Library of Congress
Introduced in House
IntroReferral
1000
2021-03-12
9
Library of Congress
Introduced in House
IntroReferral
B001275
8
Larry
Rep. Bucshon, Larry [R-IN-8]
N
Bucshon
R
IN
P000608
52
Scott
Rep. Peters, Scott H. [D-CA-52]
Peters
H.
D
2021-03-12
CA
Drug safety, medical device, and laboratory regulation Government information and archives Health personnel Licensing and registrations Medical education Prescription drugs
2021-03-12
Introduced in House
 <p><b>Advancing Education on Biosimilars Act of 2021</b></p> <p>This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)<br> <br> The FDA may also maintain and operate a website to provide educational materials about biological products.</p>
2021-05-24T13:43:19Z
00
Advancing Education on Biosimilars Act of 2021
Advancing Education on Biosimilars Act of 2021
Display Title
IH
Introduced in House
To educate health care providers and the public on biosimilar biological products, and for other purposes.
Official Title as Introduced
IH
Introduced in House
Advancing Education on Biosimilars Act of 2021
Short Title(s) as Introduced
2021-03-16
Referred to the Subcommittee on Health.